Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-08-21 Governance Information
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
利润分配管理制度
Governance Information Classification · 95% confidence The document is titled "利润分配管理制度" (Profit Distribution Management System) and details the company's policies and procedures regarding profit distribution, dividend policies, and related governance. It includes sections on the decision-making process, supervisory mechanisms, and disclosure requirements. The document is a formal policy statement approved by the board and intended for shareholder approval. It does not contain financial statements, earnings data, or audit opinions. It is not an announcement of a report publication but a detailed internal policy document. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-21 Chinese
信息披露暂缓、豁免管理制度
Governance Information Classification · 95% confidence The document is a formal announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the adoption of an internal management system for information disclosure delay and exemption. It details the company's policies and procedures for handling confidential information and regulatory compliance related to disclosure. The document includes board meeting approval details and legal references but does not contain financial statements, earnings data, or investor presentation content. It is a governance-related policy document rather than a financial report or announcement of voting results. Therefore, it fits best under Governance Information (CGR). The document length is 2452 characters, which is relatively short but contains substantive governance content, not just an announcement of a report publication or regulatory filing. Hence, the classification is CGR with high confidence.
2025-08-21 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '北京三元基因药业股份有限公司 投资者关系管理制度' which translates to 'Investor Relations Management System' of the company. It details the company's policies, principles, and procedures for managing investor relations, including communication methods, responsibilities, and compliance with regulatory requirements. It is a governance-related document outlining internal rules and practices for investor relations management. There is no financial data, earnings information, audit results, or voting results presented. It is not an announcement of a report but a detailed policy document. Therefore, it fits best under Governance Information (CGR). The document length (6921 characters) supports it being a full policy document rather than a brief announcement or notice.
2025-08-21 Chinese
关于取消监事会并拟修订《公司章程》公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the cancellation of the supervisory board and proposed amendments to the company's articles of association (公司章程). It includes extensive legal and regulatory references, detailed changes to corporate governance rules, shareholder rights, board responsibilities, and procedural rules for shareholder meetings. The content is focused on governance structure and internal company rules rather than financial results, audit opinions, or capital changes. There is no indication that this is a full annual report, audit report, earnings release, or capital update. The document is not a brief announcement or a proxy solicitation but a comprehensive governance-related document. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail support a high confidence in this classification.
2025-08-21 Chinese
累积投票管理制度实施细则
Governance Information Classification · 95% confidence The document is titled "北京三元基因药业股份有限公司 累积投票管理制度实施细则" which translates to "Beijing Sanyuan Gene Pharmaceutical Co., Ltd. Cumulative Voting Management System Implementation Rules." It details the rules and procedures for cumulative voting in the election of directors, including voting principles, election procedures, and special operational procedures. It references the company's articles of association and relevant laws. The document is a governance-related policy document about board election procedures, not a report of financial results, audit, or meeting minutes. It is not an announcement of voting results or a proxy solicitation. The content fits the category of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-08-21 Chinese
会计师选聘制度
Governance Information Classification · 95% confidence The document is titled '会计师选聘制度' which translates to 'Auditor Selection System' and details the procedures, requirements, and governance related to the selection and appointment of the company's auditing firm. It includes sections on the responsibilities of the audit committee, evaluation criteria for auditors, and procedures for changing auditors. The document is a policy or governance document related to audit firm selection rather than an audit report itself or an annual report. It does not contain financial statements or audit opinions but rather internal rules and procedures. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2025-08-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.